Perphenazine Clinical Trials

Size	Price	Qty
100mg	USD 147
500mg	USD 347

Clinical Trials

Multiple clinical trials evaluate perphenazine across Phase 1 to Phase 4 research, predominantly targeting schizophrenia, co-morbid cocaine dependence, acute ischemic stroke, dementia, and mood disorders. Sponsored by academic, government, and industry entities—including the National Institute of Mental Health, Maastricht University, and BioLineRx—these studies encompass completed evaluations of comparative antipsychotic therapies alongside protocols listed as terminated, withdrawn, or of unknown status.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04606264	COMPLETED	Perioperative Optimization	Jennifer Holder-Murray	2023-05-15	PHASE3
NCT05762146	UNKNOWN	Ischemic Stroke, Acute	Maastricht University	2022-09-05	PHASE2
NCT03510325	COMPLETED	Schizophrenia	Shanghai Mental Health Center	2019-02-12	PHASE3
NCT04776499	COMPLETED	Drug Drug Interaction; Safety Issues	Maastricht University	2021-03-18	PHASE1
NCT02431702	COMPLETED	Schizophrenia; Psychotic Disorders	Janssen Scientific Affairs, LLC	2015-07-08	PHASE3
NCT02374567	TERMINATED	Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders	Hannover Medical School	2015-01	PHASE3
NCT03019887	COMPLETED	Schizophrenia Relapse	Juntendo University	2011-04
NCT02307396	COMPLETED	Schizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders	Technical University of Munich	2015-02-01	PHASE4
NCT02199743	COMPLETED	Schizophrenia; Schizoaffective Disorder	University of Texas Southwestern Medical Center	2013-02	PHASE4
NCT00806234	COMPLETED	Psychotic Disorders	Johns Hopkins University	2009-01	PHASE4
NCT01157351	COMPLETED	Schizophrenia	Janssen Scientific Affairs, LLC	2010-05	PHASE4
NCT00737256	UNKNOWN	Schizophrenia; Cocaine Dependence	Paul Saenger	2008-08	PHASE2
NCT01193166	WITHDRAWN	Schizophrenia	Ortho-McNeil Janssen Scientific Affairs, LLC	2010-08	PHASE4
NCT00802100	COMPLETED	Schizophrenia	National Institute of Mental Health (NIMH)	2008-12	PHASE4
NCT00493233	COMPLETED	Schizophrenia	Centre for Addiction and Mental Health	2006-11
NCT00737256	Unknown status	Schizophrenia\|Cocaine Dependence	Paul Saenger\|Denver Research Institute	2008-08	Phase 2
NCT00009204	COMPLETED	Dementia; Alzheimer Disease; Dementia, Vascular	Bruce Pollock	1995-09	PHASE3
NCT00480246	COMPLETED	Healthy	BioLineRx, Ltd.	2007-05	PHASE1
NCT00014001	COMPLETED	Schizophrenia	National Institute of Mental Health (NIMH)	2000-12	PHASE4

(data from https://clinicaltrials.gov, updated on 2026-05-28)

Check the Perphenazine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Perphenazine functions as a phenothiazine derivative that selectively binds to and antagonizes postsynaptic dopamine D2 receptors, thereby inhibiting dopamine-mediated cAMP accumulation and intracellular signal transduction. This attenuation of central dopaminergic signaling reduces hyperactive mesolimbic neurotransmission, underlying its therapeutic efficacy observed in clinical trials for schizophrenia and associated psychiatric disorders.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).